CPIX
CumberlandBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The bull case is that the May 5 update kept the strategic transaction intact, left gross consideration at $100 million, and preserved the ifetroban pipeline as residual upside. If the sale closes on acceptable terms and Cumberland then delivers systemic sclerosis data, clearer DMD/FDA progress, or a credible post-closing runway plan, the current market value could still be understating residual optionality.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
After the divestiture, the remaining equity story becomes more dependent on orphan-drug development, FDA interactions, enrollment progress, and financing discipline, all of which carry higher binary risk than the legacy commercial portfolio. [#10-K-2026-03-09]
Momentum
97
Value
61
Sentiment
24
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $4.40 · Bull $5.75 · Bear $3.10
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-08 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Why
Momentum97 · Δ7d -
Value61 · Δ7d +0.3
Sentiment24 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
97
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
61
32% active weight
Current posture
7d trendFlat
Δ7d
+0.3
Δ21d
-0.4
Sentiment
24
33% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade B. Momentum 97.0 / Value 61.2 / Sentiment 23.7
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$85.4M
Beta
-0.52
Shares Out
14.96M
P/E (TTM) · Derived
-12.4
P/S (TTM)
1.45
P/FCF (TTM)
8.97
Rev YoY
-8.7%
EPS YoY
-18.1%
Gross Margin
+84.5%
Op Margin
-7.9%
Net Debt
-$2.69M
Current Ratio
1.23
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology